Viraday (Efavirenz + Emtricitabine + Tenofovir disoproxil fumarate)

Efavirenz + Emtricitabine + Tenofovir disoproxil fumarate
Contact us for more information
Цвет:
Вариант:
Wishlist Compare
Cipla Ltd

Viraday (Efavirenz + Emtricitabine + Tenofovir disoproxil fumarate)

ManufacturerCipla LtdBrand nameViradayActive substanceEfavirenz + Emtricitabine + Tenofovir disoproxil fumarateStrength600mg + 200mg + 300mgCategoryHIVManufacturerCipla Ltd

Description  of  Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)

Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)tablets are containing active constituents which are having anti-retroviral activity drugs known as Tenofovir disoproxil fumarate, Efavirenz, Emtricitabine. Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)is a FDA approved product, which is active against HIV 1 infection condition. Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)containing components are; Efavirenz: Non nucleoside reverse transcriptase inhibitor Emtricitabine: Nucleoside reverse transcriptase inhibitors Tenofovir DF: Nucleoside reverse transcriptase inhibitors. All these drugs are involved in inhibiting reverse transcriptase enzyme which is essential for viral multiplication. Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)tablets are not considered as curable medicine, but it will diminish the amount of HIV in the body and prevent the further progression into AIDS.

INDICATIONS of  Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)

The common prescribing information of Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg) tablets is used to treat HIV-1 infection by used alone or by combining with other anti-retroviral drugs.

Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg) use is applicable for adults & pediatric patients about 12 years of age and older.

MECHANISM OF ACTION  of  Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)

Efavirenz :
Efavirenz shows hostile to retroviral movement by repressing the turn around transcriptase chemical which is basic viral RNA coordinated DNA polymerase protein. The arrangement of dynamic triphosphorylated frame is vital for the impact of efavirenz, variety happens intracellularly. In light of the cell compose show in the body is required for phosphorylation. The meddling of age of DNA duplicates of viral RNA is happened by restraining the chemical RT. This new DNA duplicates is required for new popular creation. This is closed as restraint of cell division.
Emtricitabine :
Emtricitabine is changed over into dynamic frame known as Emtricitabine 5' triphosphate which is basic for hindrance of viral multiplication. This metabolite battles with deoxycytidine 5' triphosphate, is a characteristic substrate and get converged into viral DNA which prompts chain disposal.
Tenofovir DF :
This is like Emtricitabine, tenofovir is battling with substrate called deoxyadenosine 5' triphosphate and converged into DNA of infection which may closed as restriction of RT action. At long last popular increase gets influenced. NRT is a catalyst required for virion get together, tenofovir DF causes hindrance of viral fasten stretching and to create youthful demolition of DNA translation, prompts block the viral augmentation. Tenofovir DF is a chain eliminator.

 

Absorption  of  Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)

Efavirenz plasma concentration time is 3 to 5 hours Steady state of efavirenz is reached between 6 to 10days. Emtricitabine plasma concentration time reaches within one hour. Tenofovir bioavailability occurs by 25% Maximum plasma concentration is 1.0 ± 0.4 hours.

 

Distribution  of  Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)

Volume of distribution of tenofovir is 1.3 ± 0.6L/kg. Tenofovir has low plasma protein binding capacity with the range of 0.7 to 7.2% Emtricitabine is highly bound to plasma protein by 80%. Blood plasma ratio of Emtricitabine is 1.0 Human plasma protein binding capacity of efavirenz is by 99.5 to 99.7%.

 

Metabolism   of  Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)
The metabolism of efavirenz is involved by CYP3A & CYP2B6 isoenzymes. The efavirenz metabolite is induced majorly by cytochrome isoenzymes to hydrolyzed metabolites. The metabolism of tenofovir is not mediated by cytochrome enzymes. The metabolism process of Emtricitabine is not so clear.

Excretion  of  Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)
Nearly 70% of Emtricitabine is occurred in urine, 13.7% in feces. The terminal half life period of Emtricitabine is 10 hours. The dose of tenofovir nearly 32% should be recovered in urine which is in unchanged form. The terminal half life period of tenofovir is 17 hours. Tenofovir elimination: glomerular filteration & tubular secretion. The mean half life period of efavirenz is 52 to 76 hours Elimination: urine by 14 to 34%; feces by 16 to 61%.

 


SIDE EFFECTS of  Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)

The most common adverse effects :
Severe acute aggravation of hepatitis B, Lactic acidosis & hepatomegaly with steatosis, Nervous disorders, Newly commenced or worsening of renal impairment, Rash, Liver injury, Bone defects, Immune reconstitution syndrome, Redistribution of fat.
Common side effects :
Diarrhea, Nausea, Vomiting, Fatigue, Infections & infestations, Sinusitis, Respiratory tract infections, Nasopharyngitis, Headache, Dizziness, Anxiety, Depression, Insomnia, Rash.
Lab abnormality :
Increased levels of; Cholesterol, Creatine kinase, Serum amylase, Alkaline phosphatase,, AST, ALT, Blood glucose, Glycosuria, Neutropenia, Triglycerides. Post marketing reports: Palpitations, Tinnitus , Vertigo, Gynecomastia, Abnormal vision, Constipation, Malabsorption, Asthenia, Hepatobiliary disorders, Allergy, Pancreatitis.

PRECAUTIONS  of  Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)

Safety precautions should be taken in the patients who are suspected with : Patients co infected with HIV-1 HBV Drug interactions Lactic acidosis or hepatomegaly with steatosis: Stop the treatment Co administration of some drugs: Some concomitant use of drugs should be cause adverse effects. QT prolongation: monitor ECG periodically and patients may treat with alternative medications. Psychiatric symptoms: risk factors should be frequently and provided with supportive measures Nervous symptoms: To reduce the symptoms, Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)should be taken at bed time Renal impairment: In severe condition, discontinue the treatment. Reproductive risk: Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)is contraindicated to pregnancy condition. Avoid becoming pregnant Rash: Alternative treatment should be provided Liver toxicity: Liver function test should be taken periodically Bone defects: Vitamin D supplements should be given to the patients, monitor the bone mineral density. Convulsions: Provide with anti-convulsants medication and monitor the risk of seizures. Immune reconstitution syndrome: Discontinue the therapy Redistribution of fat: Discontinue the treatment. The major risk of fat redistribution is obesity

 

DRUG INTERACTION  of  Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)

The substrate of CYP3A or CYP2B6 combined with Teevir, causes decreasing plasma concentration of these substrates. Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)with CYP3A inducers causes increasing clearance of efavirenz leads to decreasing the plasma concentrations. Co administration of Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)with drugs which reduce the renal functions may leads to increase the plasma concentration of Emtricitabine & tenofovir DF leads to increase the adverse effects. Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)tablets combined with atazanavir & other protease inhibitors, causes decreasing the effect of concentration of atazanavir and increasing the tenofovir concentration. Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)with Didanosine causes increasing effect of concentration of Didanosine Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)with other NNRTI leads to cause increasing or decreasing the effect of concentration of efavirenz. Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)with anti-coagulant, anti-convulsants, anti-depressants, or anti-fungals leads to cause decreasing the effect of concentration of these following drugs. Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)combined with any anti-infective, anti-mycobacterials, anti-malarial or calcium channel blocker causes decreasing the effect of concentration of these drugs. Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)with lipid lowering drugs, hormonal contraceptives or immuno suppressants, causes decreasing effect of concentration of these drugs.

CONTRAINDICATION  of  Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)

Anaphylactic reactions may produce due to patients may contraindicate to the component present in the Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)tablets. Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)is contraindicated to some drugs like; Voriconazole The co administration of Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)with voriconazole, efavirenz one of the active component present in Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)causes depletion of plasma concentration of voriconazole which may leads to loss of therapeutic effects.

 

OVERDOSAGE  of  Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)

Anaphylactic reactions may produce due to patients may contraindicate to the component present in the Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)tablets. Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)is contraindicated to some drugs like; Voriconazole The co administration of Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)with voriconazole, efavirenz one of the active component present in Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)causes depletion of plasma concentration of voriconazole which may leads to loss of therapeutic effects.

 

Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg) in PREGNANCY & LACTATION

Pregnancy category D Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)should not be used in pregnancy and lactating period.

 

DOSAGE  of  Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)

Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)tablets should be taken on an empty stomach at bed time. The recommended dose of Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)for both adults & pediatric patients with 12 years of age or older, one tablet should be taken as a single dose. In renal impairment: Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)is a fixed dose combination tablet, if patient may require dosage adjustment should not recommended in moderate or severe conditions with the creatinine clearance below 50ml/min. Rifampin concomitant use: Patients with weigh of 50kg or more, Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)should be combined with rifampin, by increasing dose of efavirenz 200mg/day.

STORAGE  of  Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)

Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)tablet container should be stored at 25℃ (77℉). Protect the container from moisture, heat & light .

MISSED DOSE  of  Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)

Missed dose of Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)should be avoided. In case of missed dose of Teevir, must be consult with medical practitioner and follow the instructions. Regular dosing schedule of Viraday( Efavirenz 600mg + Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg)tablet should be maintained.

 

Brand name:
Viraday
Active substance:
Efavirenz + Emtricitabine + Tenofovir disoproxil fumarate
Strength:
600mg + 200mg + 300mg
Category:
HIV
Manufacturer:
Cipla Ltd
Packaging:
30 Tablet
Product form:
Tablet

No reviews found

Write feedback
Worldwide delivery

Our company ships from India to all countries of the world.

Genuine and Authentic products

All products supplied from the manufacturer of WHO : GMP certified facilities and ISO Certified facilitates

Economical and Affordable prices

All the products are supplying from manufacturing companies of India